Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions

Journal of Hematology & Oncology

Charles J Rosser²  Evan Gomes-Giacoia³  Ge Zhang³  Adrienne Lawton⁴  Steve Goodison¹  Makito Miyake³ 

[1] Nonagen Bioscience Corp, Orlando, Florida, USA;University of Central Florida, College of Medicine, 6900 Lake Nona Blvd, Orlando, FL 32827, USA;Cancer Research Institute, MD Anderson Cancer Center Orlando, Orlando Florida, USA;Department of Pathology, Orlando Health, Orlando, Florida, USA

关键词: Renal;    JAK2;    Hypoxia;    Erythropoietin;    ERK1/2;    Cancer;   

Others  :  803177
DOI  :  10.1186/1756-8722-6-65

 received in 2013-08-22, accepted in 2013-08-24,  发布年份 2013

【 摘 要 】

Background

Erythropoietin (EPO) provides an alternative to transfusion for increasing red blood cell mass and treating anemia in cancer patients. However, recent studies have reported increased adverse events and/or reduced survival in patients receiving both EPO and chemotherapy, potentially related to EPO-induced cancer progression. Additional preclinical studies that elucidate the possible mechanism underlying EPO cellular growth stimulation are needed.

Methods

Using commercial tissue microarray (TMA) of a variety of cancers and benign tissues, EPO and EPO receptor immunohistochemical staining was performed. Furthermore using a panel of human renal cells (Caki-1, 786-O, 769-P, RPTEC), in vitro and in vivo experiments were performed with the addition of EPO in normoxic and hypoxic states to note phenotypic and genotypic changes.

Results

EPO expression score was significantly elevated in lung cancer and lymphoma (compared to benign tissues), while EPOR expression score was significantly elevated in lymphoma, thyroid, uterine, lung and prostate cancers (compared to benign tissues). EPO and EPOR expression scores in RCC and benign renal tissue were not significantly different. Experimentally, we show that exposure of human renal cells to recombinant EPO (rhEPO) induces cellular proliferation, which we report for the first time, is further enhanced in a hypoxic state. Mechanistic investigations revealed that EPO stimulates the expression of cyclin D1 while inhibiting the expression of p21^cip1 and p27^kip1 through the phosphorylation of JAK2 and ERK1/2, leading to a more rapid progression through the cell cycle. We also demonstrate an increase in the growth of renal cell carcinoma xenograft tumors when systemic rhEPO is administered.

Conclusions

In summary, we elucidated a previously unidentified mechanism by which EPO administration regulates progression through the cell cycle, and show that EPO effects are significantly enhanced under hypoxic conditions.

【 授权许可】

   
2013 Miyake et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Jiang BH, Rue E, Wang GL, Roe R, Semenza GL: Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 1996, 271:17771-17778.
• [2]Semenza GL: Hypoxia-inducible factors in physiology and medicine. Cell 2012, 148:399-408.
• [3]Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH: Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 2000, 19:5435-5443.
• [4]Maynard MA, Qi H, Chung J, Lee EH, Kondo Y, Hara S, Conaway RC, Conaway JW, Ohh M: Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J Biol Chem 2003, 278:11032-11040.
• [5]Baldewijns MM, van Vlodrop IJ, Vermeulen PB, Soetekouw PM, van Engeland M, de Bruïne AP: VHL and HIF signalling in renal cell carcinogenesis. J Pathol 2010, 221:125-138.
• [6]Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG: Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000, 2:423-427.
• [7]Groulx I, Lee S: Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein. Mol Cell Biol 2002, 22:5319-5336.
• [8]Lacombe C, Mayeux P: The molecular biology of erythropoietin. Nephrol Dial Transplant 1999, 14(Suppl 2):22-28.
• [9]Zanjani ED, Ascensao JL, McGlave PB, Banisadre M, Ash RC: Studies on the liver to kidney switch of erythropoietin production. J Clin Invest 1981, 67:1183-1188.
• [10]Egrie JC, Browne JK: Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001, 84(Suppl 1):3-10.
• [11]Wilkinson PM, Antonopoulos M, Lahousen M, Lind M, Kosmidis P, EPO-INT-45 Study Group: Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial. Br J Cancer 2006, 94:947-954.
• [12]Henke M, Laszig R, Rübe C, Schäfer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003, 362:1255-1260.
• [13]Broudy VC, Lin N, Brice M, Nakamoto B, Papayannopoulou T: Erythropoietin receptor characteristics on primary human erythroid cells. Blood 1991, 77:2583-2590.
• [14]Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, Noguchi CT: Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 1994, 91:3974-3978.
• [15]Miyake M, Lawton A, Goodison S, Urquidi V, Gomes-Giacoia E, Zhang G, Ross S, Kim J, Rosser CJ: Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers. BMC Cancer 2013, 13:322. BioMed Central Full Text
• [16]Anai S, Goodison S, Shiverick K, Hirao Y, Brown BD, Rosser CJ: Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts. Mol Cancer Ther 2007, 6:101-111.
• [17]Shinojima T, Oya M, Takayanagi A, Mizuno R, Shimizu N, Murai M: Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha. Carcinogenesis 2007, 28:529-536.
• [18]Whitfield ML, Sherlock G, Saldanha AJ, Murray JI, Ball CA, Alexander KE, Matese JC, Perou CM, Hurt MM, Brown PO, Botstein D: Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 2002, 13:1977-2000.
• [19]Anai S, Sakamoto N, Sakai Y, Tanaka M, Porvasnik S, Urbanek C, Cao W, Goodison S, Rosser CJ: Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer. Urol Oncol 2011, 29:421-429.
• [20]Samoszuk MK, Walter J, Mechetner E: Improved immunohistochemical method for detecting hypoxia gradients in mouse tissues and tumors. J Histochem Cytochem 2004, 52:837-839.
• [21]Papworth K, Bergh A, Grankvist K, Ljungberg B, Rasmuson T: Expression of erythropoietin and its receptor in human renal cell carcinoma. Tumour Biol 2009, 30:86-92.
• [22]Hedley BD, Allan AL, Xenocostas A: The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression. Clin Cancer Res 2011, 17:6373-6380.
• [23]Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, Miura O, Ihle JN: JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 1993, 74:227-236.
• [24]Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ: The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol 2008, 67:39-61.
• [25]Jeong JY, Feldman L, Solar P, Szenajch J, Sytkowski AJ: Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells. Int J Cancer 2008, 122:274-280.
• [26]Dunlop EA, Percy MJ, Boland MP, Maxwell AP, Lappin TR: Induction of signaling in non-erythroid cells by pharmacological levels of erythropoietin. Neurodegener Dis 2006, 3:94-100.
• [27]Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR, Danish Head and Neck Cancer Study Group: Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 2005, 6:757-764.
• [28]Glaspy J, Crawford J, Vansteenkiste J, Henry D, Rao S, Bowers P, Berlin JA, Tomita D, Bridges K, Ludwig H: Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010, 102:301-315.
• [29]Henke M, Mattern D, Pepe M, Bézay C, Weissenberger C, Werner M, Pajonk F: Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006, 24:4708-4713.
• [30]Ciocca DR, Calderwood SK: Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005, 10:86-103.
• [31]Sungur C: Renal cell carcinoma and erythropoietin. Ann Intern Med 1995, 123:732-733.
• [32]Morere JF, Bouillet T, Piperno-Neumann S, Tourani JM, Brunet A, Hennebelle F, Bareau JL: Treatment of advanced kidney cancer using recombinant erythropoietin. Prog Urol 1997, 7:399-402.
• [33]Morais C, Johnson DW, Vesey DA, Gobe GC: Functional significance of erythropoietin in renal cell carcinoma. BMC Cancer 2013, 13:14. BioMed Central Full Text
• [34]Osterborg A, Boogaerts MA, Cimino R, Essers U, Holowiecki J, Juliusson G, Jäger G, Najman A, Peest D: Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study. the European study group of erythropoietin (epoetin beta) treatment in multiple myeloma and non-Hodgkin's lymphoma. Blood 1996, 87:2675-2682.
• [35]Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B, Epoetin Alfa Study Group: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001, 19:2865-2874.
• [36]Pronzato P, Cortesi E, Van Der Rijt CC, Bols A, Moreno-Nogueira JA, De Oliveira CF, Barrett-Lee P, Ostler PJ, Rosso R, EPO-INT-47 Study Group: Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial. Oncologist 2010, 15:935-943.
• [37]Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB, Musil J, Aranesp 980297 Study Group: Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002, 94:1211-1220.
• [38]Hedenus M, Adriansson M, San Miguel J, Kramer MH, Schipperus MR, Juvonen E, Taylor K, Belch A, Altés A, Martinelli G, Watson D, Matcham J, Rossi G, Littlewood TJ, Darbepoetin Alfa 20000161 Study Group: Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003, 122:394-403.
• [39]Vadhan-Raj S, Mirtsching B, Charu V, Terry D, Rossi G, Tomita D, McGuire WP: Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. J Support Oncol 2003, 1:131-138.
• [40]Chang J, Couture F, Young S, McWatters KL, Lau CY: Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 2005, 23:2597-2605.
• [41]Grote T, Yeilding AL, Castillo R, Butler D, Fishkin E, Henry DH, DeLeo M, Fink K, Sullivan DJ: Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2005, 23:9377-9386.
• [42]Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005, 23:5960-5972.
• [43]Osterborg A, Brandberg Y, Hedenus M: Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study. Br J Haematol 2005, 129:206-209.
• [44]Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, Rowland KM, Alberts SR, Krook JE, Levitt R, Morton RF: Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005, 23:2606-2617.
• [45]Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V: Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. J Clin Oncol 2010, 28:2239-2245.
• [46]Aapro M, Leonard RC, Barnadas A, Marangolo M, Untch M, Malamos N, Mayordomo J, Reichert D, Pedrini JL, Ukarma L, Scherhag A, Burger HU: Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J Clin Oncol 2008, 26:592-598.
• [47]Pirker R, Ramlau RA, Schuette W, Zatloukal P, Ferreira I, Lillie T, Vansteenkiste JF: Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. J Clin Oncol 2008, 26:2342-2349.
• [48]Strauss HG, Haensgen G, Dunst J, Hayward CR, Burger HU, Scherhag A, Koelbl H: Effects of anemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer. Int J Gynecol Cancer 2008, 18:515-524.
• [49]Thomas G, Ali S, Hoebers FJ, Darcy KM, Rodgers WH, Patel M, Abulafia O, Lucci JA 3rd, Begg AC: Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs. above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 2008, 108:317-325.
• [50]Okazaki T, Ebihara S, Asada M, Yamanda S, Niu K, Arai H: Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis. Neoplasia 2008, 10:932-939.
• [51]Silver DF, Piver MS: Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: a possible oxygen effect. Gynecol Oncol 1999, 73:280-284.
• [52]Stüben G, Thews O, Pöttgen C, Knühmann K, Vaupel P, Stuschke M: Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice. J Cancer Res Clin Oncol 2001, 127:346-350.
• [53]Fujisue Y, Nakagawa T, Takahara K, Inamoto T, Kiyama S, Azuma H, Asahi M: Induction of erythropoietin increases the cell proliferation rate in a hypoxia-inducible factor-1-dependent and -independent manner in renal cell carcinoma cell lines. Oncol Lett 2013, 5:1765.
• [54]Alexanian A, Rufanova VA, Miller B, Flasch A, Roman RJ, Sorokin A: Down-regulation of 20-HETE synthesis and signaling inhibits renal adenocarcinoma cell proliferation and tumor growth. Anticancer Res 2009, 29:3819-3824.
• [55]Kozlowski JM, Fidler IJ, Campbell D, Xu ZL, Kaighn ME, Hart IR: Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res 1984, 44:3522-3529.
• [56]Gong K, Zhang N, Zhang K, Na Y: The relationship of erythropoietin overexpression with von Hippel-Lindau tumour suppressor gene mutations between hypoxia-inducible factor-1# and −2# in sporadic clear cell renal carcinoma. Int J Mol Med 2010, 26:907-912.
• [57]Ito K, Yoshii H, Asano T, Horiguchi A, Sumitomo M, Hayakawa M, Asano T: Impact of increased erythropoietin receptor expression and elevated serum erythropoietin levels on clinicopathological features and prognosis in renal cell carcinoma. Exp Ther Med 2012, 3:937-944.
• [58]Feng CC, Ding GX, Song NH, Li X, Wu Z, Jiang HW, Ding Q: Paraneoplastic hormones: parathyroid hormone-related protein (PTHrP) and erythropoietin (EPO) are related to vascular endothelial growth factor (VEGF) expression in clear cell renal cell carcinoma. Tumour Biol 2013., 19
• [59]Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK, Kleid MD, Yu H, Kabbinavar FF, Pantuck AJ, Belldegrun AS: Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res 2007, 13:7388-7393.
• [60]Mannello F, Tonti GA: Erythropoietin and its receptor in breast cancer: putting together the pieces of the puzzle. Oncologist 2008, 13:761.
• [61]Kirito K, Nakajima K, Watanabe T, Uchida M, Tanaka M, Ozawa K, Komatsu N: Identification of the human erythropoietin receptor region required for Stat1 and Stat3 activation. Blood 2002, 99:102-110.